malt soup extract (OTC)

Brand and Other Names:
  • Print

Dosing & Uses

AdultPediatric

Tablets

4 tablets PO q6hr, with liquid

Powder or Liquid

2 TBS PO q12hr x 3-4 days, then 1-2 TBS HS, 8 oz of fluid taken with each dose

Other Indications & Uses

Constipation

Tablets

Not recommended in children

Powder or liquid

1-2 TBS in milk or cereal PO qDay or q12hr x 3-4 days, then 1-2 TBS HS, 8 oz of fluid taken with each dose

>1 Month Old

1-2 teaspoonful in a single feeding

Next:

Interactions

Interaction Checker

and malt soup extract

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (1)

                • deflazacort

                  malt soup extract and deflazacort both decrease serum potassium. Use Caution/Monitor.

                Minor (1)

                • sodium picosulfate

                  malt soup extract decreases effects of sodium picosulfate by Mechanism: unspecified interaction mechanism. Minor/Significance Unknown.

                Previous
                Next:

                Adverse Effects

                Frequency Not Defined

                Flatulence

                Impaction

                Excessive bowel activity

                Previous
                Next:

                Warnings

                Contraindications

                Hypersensitivity, nausea/vomiting, bowel obstruction, appendicitis, dysphagia, fecal impaction, rectal bleeding

                Cautions

                Rule out GI obstruction/perforation before administration

                Caution with severe active ulcerative colitis

                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy Category: B

                Lactation: no data available; not absorbed, therefore it is unlikely to pose the risk in breast-feeding

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Mechanism of Action

                Bulk producing laxative

                Pharmacokinetics

                Onset: 12-72 hr

                Metabolism: hydrolyzed in the colon, absorbed and then metabolized in the liver

                Previous
                Next:

                Images

                No images available for this drug.
                Previous
                Next:

                Patient Handout

                A Patient Handout is not currently available for this monograph.
                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.